OR WAIT null SECS
December 16, 2022
Catalent is set to expand its biologics analytical services with its new facility in Durham, NC.
December 14, 2022
Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.
The objectives of the new opportunity are to improve the quality and/or use of RWD, promote better understanding of RWE study designs, and develop specific tools to evaluate aspects of RWE generation.
December 13, 2022
The approval is based on results from the pivotal EFFISAYIL 1 Phase II clinical trial.
mRNA-1273.222 has also received FDA EUA for children and adolescents between six and 17 years of age and for adults over the age of 18 years of age.
December 12, 2022
The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.
December 07, 2022
The partnership will see the pharma giants partner with researchers from A*STAR and various Singapore universities.
December 02, 2022
The European Human Medicines Directive and Regulation is due to be updated by the end of 2022, but what changes are on the cards?
Anti-obesity drugs have the potential to be the next blockbusters, according to market analysis.
December 01, 2022
Catalent has completed the expansion of its clinical supply facility located in Shanghai, China.